Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

Ann-Kathrin Oehus 1, Stephanie G. C. Kroeze 2, Nina-Sophie Schmidt-Hegemann 3, Marco M. E. Vogel 4, Simon Kirsch 5,6, Jessica Becker 7, Irene A. Burger 8, Thorsten Derlin 9, Peter Bartenstein 10, Matthias Eiber 11, Michael Mix 12, Christian la Fougère 13,14,15, Claus Belka 3,16, Stephanie E. Combs 4,17, Anca-Ligia Grosu 5,6, Arndt-Christian Müller 7, Matthias Guckenberger 2, Hans Christiansen 1 and Christoph Henkenberens 1*

Abstract

Background: A substantial number of patients will develop further biochemical progression after radical prostatectomy (RP) and salvage radiotherapy (sRT). Recently published data using prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) for re-staging suggest that those recurrences are often located outside the prostate fossa and most of the patients have a limited number of metastases, making them amenable to metastasis-directed treatment (MDT).

Methods: We analyzed 78 patients with biochemical progression after RP and sRT from a retrospective European multicenter database and assessed the biochemical recurrence-free survival (bRFS; PSA < nadir + 0.2 ng/ml or no PSA decline) as well as the androgen deprivation therapy-free survival (ADT-FS) using Kaplan-Meier curves. Log-rank test and multivariate analysis was performed to determine influencing factors.

Results: A total of 185 PSMA–PET positive metastases were detected and all lesions were treated with radiotherapy (RT). Concurrent ADT was prescribed in 16.7% (13/78) of patients. The median PSA level before RT was 1.90 ng/mL (range, 0.1–22.1) and decreased statistically significantly to a median PSA nadir level of 0.26 ng/mL (range, 0.0–12.25; p < 0.001). The median PSA level of 0.88 ng/mL (range, 0.0–25.8) at the last follow-up was also statistically significantly lower (p = 0.008) than the median PSA level of 1.9 ng/mL (range, 0.1–22.1) before RT. The median bRFS was 17.0 months (95% CI, 14.2–19.8). After 12 months, 55.3% of patients were free of biochemical progression. Multivariate analyses showed that concurrent ADT was the most important independent factor for bRFS (p = 0.01). The median ADT-FS was not reached and exploratory statistical analyses estimated a median ADT-FS of 34.0 months (95% CI, 16.3–51.7). Multivariate analyses revealed no significant parameters for ADT-FS.

Conclusions: RT as MDT based on PSMA-PET of all metastases of recurrent prostate cancer after RP and sRT represents a viable treatment option for well-informed and well-selected patients.

Keywords: PSMA, Radiotherapy, Prostate cancer, Oligometastases, Recurrence, Radical prostatectomy

© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Salvage radiotherapy (sRT) represents the standard of care for patients with a biochemical relapse after radical prostatectomy (RP) of localized prostate cancer (PCa) [1]. Nevertheless, a substantial number of patients will not benefit permanently from sRT and will develop biochemical progression [2, 3]. Recently published data suggest that early recurrences are often located outside the prostate fossa [4–6], and a large proportion of these patients (40–70%) have a limited number of metastases, making them amenable to metastasis-directed treatment (MDT) [7]. These cases are usually considered oligometastatic status and a strict clinical definition, the evidence for MDT for patients with a generally accepted imaging-based cut-off of five metastases - outside large randomized prospective trials - is consistently increasing [8, 9]. Recent data showed a positive effect on the clinical outcome for MDT with low toxicity, although staging with positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) radio ligands was not consistently increased [10, 11].

Furthermore, the successful implementation of PSMA-PET – outperforming all other imaging modalities [12] – significantly improves patient selection for MDT and subsequently leads to high acceptance of MDT in patients with limited prostate cancer recurrence [13]. PSMA-PET allows individualizing treatment concepts that aim to improve PSA progression-free survival, defer the initiation of androgen deprivation therapy ADT and potentially cure the patient [14]. In addition, the optimal timing of initiation of ADT for asymptomatic biochemically progressive disease after RP and sRT remains uncertain [1]. Importantly, it has been shown that ADT could be safely deferred in a relevant proportion of patients by MDT, which may also improve quality of life (QoL) [8, 9].

However, the potential usefulness of a PSMA-PET-guided MDT approach in the clinical setting even after sRT (i.e., in patients with a longer treatment history than in previously investigated approaches) is underexplored. Therefore, we investigated the efficacy and safety of definitive radiotherapy (RT) for PSMA-PET-detected oligometastatic disease after both RP and prior sRT in a retrospective European multicenter study.

Methods
This retrospective multicenter study was approved by the institutional review boards of all participating centers (BASEC-Nr. 2017–01499). Included patients (n = 379) were treated with definitive PSMA-PET-based RT as MDT between 04/2013 and 01/2018 in 6 academic centers in Switzerland and Germany. In the present analysis, we included 78 patients with biochemical progression after initial RP plus sRT and subsequent diagnosis of oligorecurrent PCa on the basis of PSMA-PET. All patients presented with no evidence of distant metastases (M0) at initial diagnosis and salvage radiotherapy of the prostatic bed. PCa recurrence was defined as nodal or extranodal metastases (N1 or M1a/1b/1c) in PSMA-PET. PET-CT or PET-MRI was performed with 68Ga-radiolabelled PSMA-ligand. Any PSA level at the time of RT was accepted. Oligorecurrent disease was defined as ≤5 visceral or bone metastases; there was no limit on lymph node metastases. All cases were discussed and approved for RT by the local multidisciplinary uro-oncologic boards. The patients’ characteristics are summarized in Table 1.

PET imaging
Each patient received PET imaging with a 68Ga-labeled PSMA ligand [15], and imaging was performed according to the joint EANM and SNMMI guidelines [16]. PSMA-PET scans were acquired in conjunction with either contrast-enhanced or low-dose computed tomography (PET/CT; 87.2%, 68/78) or magnetic resonance imaging (PET/MRI; 12.8%, 10/78). Visual assessment of focally increased tracer uptake higher than the surrounding background activity was used as the criterion for malignancy [8].

Radiotherapy treatment
Patients were treated with stereotactic body radiation therapy (SBRT) or with conventionally fractionated RT (CF-RT), including either a conventionally fractionated simultaneously integrated boost (SIB) or a sequential SBRT boost to the PET-positive lesion. Definitive RT was delivered to all PSMA ligand-positive lesions. Irradiation was performed at the discretion of the participating center in terms of radiation dose, elective nodal volumes, and type and length of concurrent ADT. The prescribed radiotherapy dose was converted to EQD2 in Gy using an α/β ratio of 1.5 [17].

Follow-up and endpoints
Biochemical recurrence-free survival (bRFS) was measured from the last day of RT to the diagnosis of biochemical recurrence and defined according to PSA failure after RP [18]: PSA ≥ 0.2 ng/ml above the PSA nadir following RT. When serum PSA did not respond to RT, the pre-RT level with an increase of ≥0.2 ng/ml was defined as bRFS. Follow-up was performed according to institutional protocols, with regular serum PSA measurements and clinical follow-up visits. Secondary outcomes were ADT-free survival (ADT-FS), overall survival (OS) and toxicity. The timing of imaging at biochemical recurrence after RT, as well as the initiation of local and/or systemic therapies, was at the discretion of the local multidisciplinary uro-oncologic board. RT-
associated toxicity was analyzed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [19].

Statistical analysis
For statistical analysis, SPSS Statistics v25.0 (IBM, Armonk, New York, USA) was used. We used the paired Student’s t test to compare pre-RT with post-RT parametric parameters and the Wilcoxon signed-rank test when data were not normally distributed. The time to event data was calculated using the Kaplan-Meier method. Established factors for treatment failure after sRT [20, 21] were analyzed with log rank test in univariate analyses, and significant factors were further assessed with multivariate analyses to identify independent variables for bRFS and ADT-FS. P-values of < 0.05 were considered statistically significant.

Results
Result of PSMA ligand PET staging and therapy of metastases
A total of 185 PSMA ligand positive metastases were detected and treated with RT: 41.6% (77/185) were pelvic lymph node metastases, 27.6% (51/185) were peri-aortic lymph node metastases, 24.3% (45/185) were bone metastases, and 6.5% (12/185) were visceral metastases. A total of 58.8% of patients (46/78) had only lymph node metastases, 32.1% (25/78) of patients had only bone metastases, 3.8% (3/78) of patients had lymph node and bone metastases, 2.6% (2/78) of patients had visceral metastases only, and 2.6% (2/78) of patients had visceral and lymph node metastases.

Concurrent ADT was prescribed in 16.7% (13/78) of patients and ADT was deferred in the remaining patients. Furthermore, additive chemotherapy with docetaxel was administered in 30.8% (4/13) of patients with concurrent ADT. The majority of the patients (57.7%; 45/78) received CF-RT, 20.5% (16/78) received SBRT, 12.8% (10/78) received CF-RT with SBRT boost, and 9% (7/78) of the patients were treated with CF-RT and a simultaneous integrated boost (SIB).

Table 2 summarizes the results of the PSMA ligand PET results and therapy of the metastases.

Patients’ outcome
The median follow-up was 16 months (3–54). Overall survival (OS) was 97.4% after 2 years; 2 patients died of progressive metastatic PCa. The median PSA level before RT was 1.90 ng/mL (range, 0.1–22.1) and decreased statistically significantly to a median PSA nadir level of 0.26 ng/mL (range, 0.0–12.2; \( p < 0.001 \)). The median PSA level of 0.88 ng/mL (range, 0.0–25.8) at the last follow-up was also statistically significantly lower (\( p = 0.008 \)) than the median PSA level of 1.9 ng/mL (range, 0.1–22.1) before RT. Moreover, 20.5% (16/78) of all patients had a PSA level < 0.07 ng/mL at the last available follow-up. Nine of these 16 patients (56.3%) were ADT naive.
A total of 57.7% (42/78) of patients were classified as having biochemically progressive disease after RT. The median PSA level at biochemical progression was 0.37 ng/mL (range, 0.1–3.6). The median bRFS was 17.0 months (95% CI, 14.2–19.8; Fig. 1). After 12 months, 55.3% of patients were free of biochemical progression. Multivariate analyses showed that concurrent ADT was the most important independent factor for bRFS ($p = 0.01$). The detailed results of the statistical analyses are shown in Table 3. Furthermore, 83.3% (35/42) of patients with biochemically progressive disease underwent restaging, which was performed with the exception of one patient (2.9%) with PSMA - PET. The staging revealed new metastases in 85.7% (30/35) of patients and in 14.3% (5/35) of patients PSMA – PET detected no metastases. The resulting treatment concepts for patients with biochemical progression were as follows: in 50% (21/42) of patients, ADT was initiated, and 14.3% (6/42) of patients started observation with regular PSA measurements, and in 9.5% (4/42) of patients, repeated RT was performed. Furthermore, 9.5% (4/42) of patients received ADT plus repeated RT; 7.1% (3/42) of patients received taxane-based chemotherapy, and 2.4% (1/42) of patients received taxane-based chemotherapy plus ADT. Additionally, in 4.8% (2/42), a therapy with radium-223 dichloride was initiated, and 2.4% (1/42) of patients received a secondary hormonal ablation with enzalutamide.

For ADT-FS analyses, patients among ADT at time of RT (3.9%; 3/78) or patients who received concurrent ADT +/- docetaxel (16.7%; 13/78) for RT were excluded. The median ADT-FS was not reached because less than half of the patients (38.7%; 24/62) were in need of ADT at their last follow-up visit. Exploratory statistical analyses estimated a median ADT-FS of 34.0 months (95% CI, 16.3–51.7, Fig. 2). None of the significant parameters of the univariate analyses reached significance in multivariate analyses. The detailed results of the statistical analyses are shown in Table 4.

**Toxicity**

Acute grade III toxicity was not observed; 1.3% (1/78) of patients developed acute genitourinary toxicity grade II. Acute gastrointestinal toxicity grade II occurred in 1.3% (1/78) of patients, and acute gastrointestinal toxicity grade I occurred in 1.3% (1/78) of patients. Late grade III gastrointestinal toxicity occurred in 1.3% (1/78) of patients, and grade II genitourinary toxicity in 1.3% (1/78) of patients.

**Discussion**

The implementation of PSMA ligand imaging has substantially improved the diagnostic accuracy for the detection of (oligo) metastatic PCa at low PSA levels [5, 22], leading to the recent guidelines by the European Organization for Research and Treatment of Cancer (EORTC) demanding modern imaging methods for trials investigating MDT in oligometastatic PCa [23]. Although large randomized prospective studies are lacking, approximately two-thirds of the experts at the 2017 Advanced Prostate Cancer Consensus Conference considered MDT...
as a treatment option for patients with oligorecurrent PCa [13].

A substantial number of patients will develop further biochemical progression after sRT [2, 3], and controversy still exists about the optimal timing of initiation of palliative ADT regarding asymptomatic metastatic patients because of the lack of prospective trials from the PSA era [1]. Furthermore, ADT alone offers no curative potential [1] and significantly impairs QoL in a relevant number of patients [24]. Therefore, MDT to all detectable lesions might shift the treatment concept from palliative to potentially curable [10]. Smaller prospective trials with heterogeneous patient collectives, one with choline PET imaging [10], one with PSMA ligand PET imaging [25] and one with sodium fluoride (NA-F) PET imaging [11], showed encouraging results for MDT for oligometastatic prostate cancer.

To the authors’ best knowledge, the assessed subset from a large retrospective multicenter database including only patients with oligometastatic disease after RP and sRT treated with PSMA ligand guided RT is the first analysis that showed a significant improvement of the PSA levels. The median PSA levels at the last follow-up visit were significantly lower than the PSA levels prior to RT (1.90 vs. 0.88; p = 0.008). Furthermore, a significant number of patients receiving RT alone could be spared
ADT treatment for an estimated median time of 34 months. Our results are better than the results of the STOMP trial, which showed a median ADT-FS of 13.0 months. However, for the STOMP trial, the median PSA was 5.3 ng/ml, and PSMA ligand imaging was not available, thereby decreasing the likelihood of identifying a truly oligometastatic cohort of patients [10]. The POPSTAR trial reported a 2-year ADT-FS of 48%, which is slightly worse than the results we observed, possibly due to a higher proportion of patients with bone metastases. Furthermore, imaging was performed with Na-F PET. Na-F PET imaging outperforms conventional imaging for bone metastases but cannot depict nodal metastases, increasing the likelihood of including patients with bone metastases but underestimating lymph node metastases, possibly leading to a patient cohort with unfavorable prognosis [11].

Table 3 Results of uni- and multivariate analyses for biochemical progression-free survival (bRFS)

| Variable                                      | Univariate analysis | Multivariable analysis |
|-----------------------------------------------|---------------------|------------------------|
| Initial T stage (≤T2 vs ≥T3)                  | 0.02                | 0.50                   |
| Initial N stage (N0 vs N1)                    | 0.07                | 0.07                   |
| Initial PSA level in ng/ml (≤20 vs > 20)      | 0.36                |                        |
| PSA nadir after RP (≤0.07 ng/mL vs > 0.07 ng/mL) | 0.04               | 0.14                   |
| Number of removed LN at RP (≤15 vs > 15)      | 0.32                |                        |
| Initial Risk Group (intermediate+high risk vs. very high risk) | 0.15 | |
| PSA doubling time (≤6 months, > 6 months)     | 0.46                |                        |
| Radiotherapy type (CF-RT vs. SBRT)            | 0.11                |                        |
| No. of irradiated metastases (1 vs >1)        | 0.37                |                        |
| Type of metastases (lymph node vs bone)       | 0.18                |                        |
| Concurrent ADT (yes vs no)                    | 0.03                | 0.01                   |
| RT-Dose (≤50 Gy vs > 50 Gy)                   | 0.74                |                        |

ADT, androgen deprivation therapy; CF-RT, conventionally fractionated radiotherapy type; dt, doubling time; Gy, Gray; LN, lymph nodes; PSA, prostate-specific antigen; RP, radical prostatectomy; sRT, salvage radiotherapy; SBRT, stereotactic body radiation therapy; SIB, simultaneous integrated boost.
The administration of concurrent ADT in this situation is currently unknown. RT with concurrent ADT might improve bRFS and OS for patients with low-volume disease according to the CHAARTED criteria as extrapolated from the Stampede trial [26], although the study only included patients treated with slightly hypofractionated RT of the prostate. Furthermore, the study protocol provided no local therapies to asymptomatic metastases. On the other hand, the STOMP [10] and POPSTAR trials [11], as well as the data published by Kneebone et al. [25], demonstrated that MDT alone might delay ADT for a relevant period. However, patients with MDT alone develop biochemical progression earlier than patients with MDT plus ADT. The impact on OS of MDT alone remains unknown due to the short follow-up and small sample sizes in the few prospective trials [10, 11, 25]. There might be concern that patients who do not respond well to MDT might develop widespread metastases with unfavorable prognoses. On the other hand, approximately half of the patients will develop oligoprogressive disease after MDT [10], making these patients amenable to repeated MDT [27]. Furthermore, the presented cohort had PSMA ligand imaging for staging purposes, and fewer metastases should be missed compared to conventional imaging and choline PET [4, 5, 22], indicating well-selected patients. Moreover, no data about the biological evolution of prostate cancer are available in the context of prior local therapies such as RP and sRT. Exploratory analyses for patients with metachronous metastases after initial curative local therapy revealed no OS benefit for escalated systemic therapy using either the combination of ADT + docetaxel [28, 29] or ADT + enzalutamide [30] compared to ADT alone, indicating a different biology.

We did not find a statistically significant predictor for ADT-FS in multivariate analyses, such as location (bone vs. lymph node) or number of metastases. Neither Ost et al. [10] nor Kneebone et al. [25] identified any clinical parameter significantly associated with prolonged ADT-FS, likely because the number of enrolled patients (62 and 57, respectively) was too small for sufficient statistical subgroup analyses. Nevertheless, a recently published SEER database analysis suggested that patients with M1a tumor stage have a significantly greater clinical benefit from local therapies to the prostate than patients with M1b tumor stage [31]. Additionally some patients presented with progression among ADT at PSMA ligand staging and must be considered as early castration-resistant. Data about RT as MDT on this oncological situation are rare, although Berghen et al. recently yielded first information that RT substantially postponed next-line systemic treatment [32]. In general the definition of oligometastases for prostate cancer is controversial and there is no general agreement between different experts panels [13, 33]. The hypothesis generating phase II STOMP trial included patients up to three nodal or bone metastases based upon Choline PET staging [10], whereas the expert panel of the APCCC 2017 did not reach consensus regarding a numerical definition of oligometastasis, and 61% of the panelists voted for a limited number of bone and/or lymph nodes metastases that influences treatment decisions [13]. The expert panel of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) reached a consensus of 100% for metachronous oligometastatic castration-sensitive prostate cancer with primary tumor controlled and up to three metastases (node or bone) [33]. Particularly in comparison to the latter results of the AIRO expert panel, we used a broader definition of oligometastases and included patients with a

### Table 4

| Result of uni- and multivariate analyses for androgen deprivation therapy-free survival (ADT-FS) | Univariate analysis | Multivariable analysis |
|---|---|---|
| Parameter | p value | p value | OR (95% CI) |
| Initial T stage (T2 vs ≥ T3) | 0.07 | 0.20 | 2.02 (0.68–5.99) |
| Initial N stage (N0 vs N1) | 0.95 | 0.02 | 2.58 (0.8–7.98) |
| Initial PSA level in ng/ml (≤ 20 vs > 20) | 0.05 | 0.05 | 5.99 (0.96–36.72) |
| PSA nadir after RP (≤ 0.07 ng/mL vs > 0.07 ng/mL) | 0.31 | 0.26 | 0.79 (0.32–2.01) |
| Number of removed LN at RP (≤ 15 vs > 15) | 0.26 | 0.10 | 1.01 (0.98–1.04) |
| Initial risk group (intermediate+high risk vs. very high risk) | 0.12 | 0.05 | 0.20 (0.08–0.48) |
| PSA dt (≤ 6 months vs > 6 months) | 0.10 | 0.10 | 1.01 (0.98–1.04) |
| Radiotherapy type (CF-RT vs. SBRT) | 0.73 | 0.51 | 1.01 (0.98–1.04) |
| No. of irradiated metastases (1 vs > 1) | 0.12 | 0.12 | 1.01 (0.98–1.04) |
| Type of metastases (Lymph node vs bone) | 0.44 | 0.44 | 1.01 (0.98–1.04) |
| RT dose (≤ 50 Gy vs > 50 Gy) | 0.44 | 0.44 | 1.01 (0.98–1.04) |
| PSA nadir after RP (≤ 0.07 ng/mL vs > 0.07 ng/mL) | 0.05 | 0.05 | 5.99 (0.96–36.72) |

**ADT** androgen deprivation therapy, **CF-RT** conventionally fractionated radiotherapy type, dt doubling time, Gy Gray, LN lymph nodes, PSA prostate-specific antigen, RP radical prostatectomy, sRT salvage radiotherapy, SBRT stereotactic body radiation therapy, SIB simultaneous integrated boost
more advanced cancer burden. Furthermore, we there was no limit on lymph node metastases. Therefore, we cannot rule out that some patients had little benefit due to our definition of oligometastatic PCs. On the other hand the observed clinical outcomes are promising and prospective trials using PSMA ligand staging will have to investigate that.

The retrospective nature has inherent limitations and might have introduced selection bias. Furthermore, the median follow-up of 16 months and the sample size of 78 patients limited the statistical power, although the observed clinical results are robust and contribute significantly to the discussion of PSMA ligand guided MDT after RP and sRT in a quickly changing clinical field. In addition, the study included a selected cohort with mainly high-risk patients. Therefore, caution should be taken when generalizing the observed results for patients with intermediate- or low-risk PCs. Because we used clinical real-life data from an observational study, the RT treatment was heterogeneous regarding radiotherapy dose and field size, as well as the use of concurrent ADT. Prospective trials investigating the addition of ADT, the size of RT fields and the radiotherapy dose are warranted objectives in the field of relapsed PCs after RP and sRT at this time.

Conclusion
Even in a clinical setting after both RP and prior sRT, PSMA - PET-based RT for recurrent PCs with limited tumor burden was effective and safe. RT alone delayed the initiation of ADT longer than in other cohorts. RT of all lesions after RP and sRT based on PSMA - PET represents a viable treatment option for well-informed and well-selected patients, including a close follow-up schedule, particularly after RT alone.

Abbreviations
ADT: Androgen deprivation therapy; ADT-FS: Androgen deprivation therapy-free survival; bRFS: Biochemical recurrence-free survival; CF-RT: Conventionally fractionated RT; CTCAE: Common Terminology Criteria for Adverse Events; Dt: Doubling time; EORTC: European Organization for Research and Treatment of Cancer; Gy: Gray; LNs: Lymph node metastases; MDT: Metastasis-directed treatment; NA-F: Sodium fluoride; OS: Overall survival; PSA: Prostate-specific antigen; PCA: Prostate cancer; PET: Positron emission tomography; PSMA: Prostate-specific membrane antigen; PSMA PET: Prostate-specific membrane antigen ligand positron emission tomography; QoL: Quality of life; RP: Radical prostatectomy; RT: Radiotherapy; SBRT: Stereotactic body radiation therapy; SIB: Simultaneously integrated boost; sRT: Salvage radiotherapy

Acknowledgements
None.

Authors’ contributions
AKO and CH had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: AKO and CH Acquisition of data: AKO, HC, CB, MG. Drafting of the manuscript: AKO CH. Critical revision of the manuscript for important intellectual content: ALG, SEC, ACM, HC, CB, MG, IAB, TD, PB, ME, MM. CIF. Statistical analysis: AKO, CH. The author(s) read and approved the final manuscript.

Funding
None.

Availability of data and materials
Please contact the corresponding author for study data, which will be granted upon reasonable request.

Ethics approval and consent to participate
The presented retrospective study was approved by all local institutional ethics committees (Medical School Hannover, University Hospital Zurich, University Hospital Freiburg, University Hospital of the Technical University Munich, University Hospital of the Ludwig-Maximilians-University Munich and the University Hospital Tübingen). All patients gave written informed consent to participate.

Consent for publication
Not Applicable.

Competing interests
All authors declare that they have no conflict of interest.

Author details
1Department of Radiotherapy and Special Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30629 Hanover, Germany. 2Department of Radiation Oncology, University Hospital Zürich, University of Zurich, Zürich, Switzerland. 3Department of Radiation Oncology, University Hospital LMU Munich, Munich, Germany. 4Department of Radiation Oncology, Technical University Munich, Munich, Germany. 5Department of Radiation Oncology, University of Freiburg, Freiburg, Germany. 6German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany. 7Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany. 8Department of Nuclear Medicine, University Hospital Zürich, Zürich, Switzerland. 9Department of Nuclear Medicine, Hannover Medical School, Hanover, Germany. 10Department of Nuclear Medicine, University Hospital LMU Munich, München, Germany. 11Department of Nuclear Medicine, Technical University Munich, München, Germany. 12Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany. 13Department of Nuclear Medicine, University Hospital Tübingen, Tübingen, Germany. 14Cluster of Excellence I4T (EXC 2180) “Image Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Tübingen, Germany. 15German Cancer Consortium (DKTK) Partner Site Tübingen, Tübingen, Germany. 16German Cancer Consortium (DKTK) Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany. 17Institute of Innovative Radiotherapy (iRT), Oberschleißheim, Germany.

Received: 20 January 2020 Accepted: 21 April 2020
Published online: 29 April 2020

References
1. Conford P, Bellmunt J, Bolla M, Briers E, De Santis M, Goss T, et al. EAU-ESTRO-SIOG guidelines on prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate Cancer. Eur Urol. 2017;71(4):630–42.
2. Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17(6):747–56.
3. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without Androgen therapy in recurrent prostate Cancer. N Engl J Med. 2017;376(5):417–28.
4. van Leeuwen PJ, Stricker P, Huwy G, Kneebone A, Ting F, Thompson B, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117(5):732–9.
5. Calais J, Czemin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. (68)Ga-PSMA-11 PET/CT mapping of prostate Cancer biochemical recurrence after
radical prostectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59(2):230–7.

6. Schmidt-Hegemann NS, Eze C, Li M, Rogowski P, Schaefer C, Stief C, et al. Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. J Nucl Med. 2019;60(7):963–70.

7. Roach P, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The impact of 68Ga-PSMA PET/CT on management intent in prostate Cancer: results of an Australian prospective multicenter study. J Nucl Med. 2018;59(1):82–8.

8. Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017;116(12):1520–5.

9. Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, et al. Surveillance or metastasis-directed therapy for Oligometastatic prostate Cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–53.

10. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Stereotactic Abative body radiotherapy (SABR) for Oligometastatic prostate Cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455–62.

11. Siva S, Bressel M, Murphy DG, Shaw M, Chandler S, Violet J, et al. Stereotactic Abative body radiotherapy (SABR) for Oligometastatic prostate Cancer: a multicenter prospective clinical trial of 68Galium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: Oligometastatic rate and distribution compared with standard imaging. Int J Radiat Oncol Biol Phys. 2019;104(4):801–8.

12. Gillissen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of Patients with advanced prostate Cancer: the report of the advanced prostate Cancer consensus conference APCCC 2017. Eur Urol. 2018;73(2):178–211.

13. Tosioan JJ, Gorin MA, Ross AE, Planta JT, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(11):15–25.

14. Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Bengel FM, Schaefer C, et al. 68Ga-PSMA-11 (HBED-CC) PET/CT in prostate Cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(11):1080–7.

15. Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wängler C, Mier W, et al. 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24.

16. Baumann M, Höltzcher T, Denham J. Fractionation in prostate cancer—is it time after all? Radiother Oncol. 2010;96(1):1–10.

17. Thompson WM, Valicenti RK, Albertsen P, Davis BJ, Azimi M, Iglewicz B, et al. Progression-directed Therapy for Oligometastatic prostate Cancer. Lancet. 2018;392(10162):2353–66.

18. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy (STAMEPE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMEPE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–66.

19. Morgans AK, Stockler MR. Patient-reported outcomes in metastatic castration-sensitive prostate Cancer in the adjuvant setting. Eur Urol Focus. 2019;5(2):144–6.

20. Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, et al. Stereotactic body radiotherapy for Oligometastatic prostate Cancer detected via prostate-specific membrane antigen positron emission tomography: Eur Urol Oncol. 2018;16(1):531–7.

21. Nuhn P, De Bonis JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate Cancer therapies: Management of Metastatic Castration-resistant Prostate Cancer in the era of precision oncology. Eur Urol. 2019;75(1):88–99.

22. Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wängler C, Mier W, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in prostate Cancer treated with stereotactic body radiotherapy: evaluation of drug efficacy (STAMEPE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMEPE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–66.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

23. Note
Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions